市場調査レポート

商品コード

1423556

ガバペンチン市場の2030年までの予測：製品タイプ、投与経路、購入形態、用途、エンドユーザー、地域別の世界分析

Gabapentin Market Forecasts to 2030 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography

出版日: 2024年02月02日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 650,305円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 822,675円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 995,045円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,175,250円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.70円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、ガバペンチンの世界市場は2023年に21億7,152万米ドルを占め、予測期間中のCAGRは7.4％で成長し、2030年には35億6,761万米ドルに達すると予測されています。

ガバペンチンは、神経伝達物質であるγ-アミノ酪酸（GABA）を模倣し、主に抗けいれん薬として、また神経障害性疼痛の緩和に使用される医薬品です。米国食品医薬品局（FDA）により承認されており、てんかん、帯状疱疹後神経痛、レストレスレッグス症候群など様々な疾患の治療に用いられています。神経疾患や慢性疼痛に対応する汎用性の高さから、現代医療における貴重な財産となっています。

報告によると、ガバペンチンは2020年に米国で処方された薬の中で第6位にランクされています。2020年には、米国で5,700万件の処方箋が作成される見込みです。

認知度の向上

ヘルスケア専門家や患者は、様々な神経疾患や神経因性疼痛状態の管理におけるこの薬剤の有効性について、より多くの情報を得るようになってきています。医師は、ガバペンチンの作用機序や効果的に対処できる多様な症状に対する理解を深め、ガバペンチンを処方するようになってきています。加えて、患者中心のヘルスケアは進化しており、十分な情報に基づいた意思決定が奨励されているため、この市場を牽引する重要な要因となっています。

誤用と乱用

ガバペンチンの誤用には、処方された量を超えて服用すること、処方箋なしで使用すること、望ましい効果を強めるために他の物質と併用することなどが含まれます。ガバペンチンの乱用は、めまい、鎮静、協調運動障害、目のかすみ、認知障害など、さまざまな副作用を引き起こす可能性があります。さらに、誤用や乱用が長期化した後にガバペンチンを突然中止すると、不安、不眠、落ち着きのなさなどの離脱症状が現れ、この市場の拡大を大きく妨げることになります。

遠隔医療サービスの拡大

遠隔医療サービスの拡大はヘルスケアに貢献し、神経疾患や神経因性疼痛でガバペンチンを必要とする患者への容易な投与を実現することで、この薬へのアクセスにプラスの影響を与えます。遠隔医療は、ヘルスケア提供者が遠隔地から診察を行い、薬を処方し、患者の状態をモニターすることを可能にします。さらに、遠隔医療はヘルスケア専門家が遠隔で患者を監視し、懸念に迅速に対処し、投薬管理を最適化することを可能にし、これがこの市場を推進しています。

副作用と耐性

副作用の蔓延は、ガバペンチンの治療上の利点とその潜在的な欠点とのバランスをとる上で、ヘルスケア提供者に課題を突きつけています。年齢、基礎疾患、併用薬などの患者固有の要因は、副作用の可能性と重症度に影響する可能性があります。さらに、副作用の存在は、追加の医療介入を必要とする可能性があり、医療費と資源利用の一因となるため、市場成長の妨げとなります。

COVID-19の影響

COVID-19の大流行はガバペンチン市場にいくつかの悪影響を与えました。サプライチェーンの混乱、封鎖措置、ヘルスケアの優先順位のシフトは、総じてガバペンチンの生産、流通、消費における課題の一因となった。経済的な不確実性とヘルスケアシステムに対する財政的なひずみがコスト削減を促し、ガバペンチンの値ごろ感に影響を与える可能性があります。さらに、医療機関を訪れる患者の減少が新規処方や再処方の減少につながり、市場全体の需要に影響を与えている可能性もあります。

予測期間中、カプセル・セグメントが最大となる見込み

最大のシェアを占めると推定されるのはカプセル剤です。これらは、てんかん、帯状疱疹後神経痛、糖尿病性神経障害などの症状を効率的に管理する、神経疾患や神経因性疼痛に広く処方される医薬品です。研究開発イニシアティブ、規制当局の承認、戦略的提携などの要因が市場ダイナミクスに影響を与えます。さらに、技術革新、安全性、アクセシビリティへの注力は、より広範な医薬品市場の重要な貢献者であり続け、このセグメントの成長を牽引しています。

予測期間中にCAGRが最も高くなると予想される非経口用医薬品セグメント

非経口剤セグメントは、特に吐き気や嘔吐、嚥下困難な患者など、経口摂取が困難な状況において明確な利点があるため、予測期間中にCAGRが最も高くなると予想されます。この投与方法は、治療のコンプライアンスを高め、患者が処方された用量を正確に受け取れるようにします。さらに、迅速な作用発現や正確な投与量管理が必要な患者には、ガバペンチンの非経口製剤が効果的な代替手段となり、このセグメントの拡大を後押ししています。

最もシェアの高い地域

北米は、神経疾患や神経因性疼痛に対応する医薬品市場において大きな存在感を示しているため、予測期間中に最大の市場シェアを獲得しました。Pfizer Inc.、Teva Pharmaceuticals Ltd.、Glenmark Pharmaceuticals Limited、Cipla USA Inc.などの主要市場は、てんかん、帯状疱疹後神経痛、糖尿病性神経障害などの疾患管理の要となっています。さらに、米国食品医薬品局（FDA）やカナダ保健省（Health Canada）などの規制監督機関が、この地域における安全基準の遵守と効果的な流通を保証しています。

CAGRが最も高い地域：

欧州は、てんかん、帯状疱疹後神経痛、糖尿病性ニューロパチーのような症状の管理に有効であることから、予測期間中に最も高いCAGRを示すと予想されます。製薬会社は、欧州で神経症状と闘う人々に効果的な解決策を提供するため、ガバペンチンの需要増に対応する製造・マーケティング活動に従事しています。さらに、神経疾患の有病率の上昇、人口の高齢化、慢性疼痛管理に対する意識の高まりなどの要因が、この地域の拡大を後押ししています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第12章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第13章企業プロファイル

Amneal Pharmaceuticals LLC.
Intas Pharmaceuticals Ltd.
Sun Pharmaceutical Industries Ltd
Marksans Pharma
Novartis AG
Alkem Labs
Jiangsu Nhwa Pharmaceutical Co., Ltd
Aurobindo Pharma
Apotex Inc
Viatris Inc
Arbor Pharmaceuticals, LLC
Pfizer Inc
Teva Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited
Ascend Laboratories, LLC
Cipla USA, Inc.

図表

List of Tables

Table 1 Global Gabapentin Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Gabapentin Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
Table 4 Global Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
Table 5 Global Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
Table 6 Global Gabapentin Market Outlook, By Type (2021-2030) ($MN)
Table 7 Global Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
Table 8 Global Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
Table 9 Global Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
Table 10 Global Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 11 Global Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
Table 12 Global Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
Table 13 Global Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
Table 14 Global Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 15 Global Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
Table 16 Global Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
Table 17 Global Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
Table 18 Global Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
Table 19 Global Gabapentin Market Outlook, By Application (2021-2030) ($MN)
Table 20 Global Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
Table 21 Global Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
Table 22 Global Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
Table 23 Global Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
Table 24 Global Gabapentin Market Outlook, By End User (2021-2030) ($MN)
Table 25 Global Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 26 Global Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 27 Global Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
Table 28 North America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
Table 29 North America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
Table 30 North America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
Table 31 North America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
Table 32 North America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
Table 33 North America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
Table 34 North America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
Table 35 North America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
Table 36 North America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
Table 37 North America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 38 North America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
Table 39 North America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
Table 40 North America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
Table 41 North America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 42 North America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
Table 43 North America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
Table 44 North America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
Table 45 North America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
Table 46 North America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
Table 47 North America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
Table 48 North America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
Table 49 North America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
Table 50 North America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
Table 51 North America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
Table 52 North America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 53 North America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 54 North America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
Table 55 Europe Gabapentin Market Outlook, By Country (2021-2030) ($MN)
Table 56 Europe Gabapentin Market Outlook, By Product (2021-2030) ($MN)
Table 57 Europe Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
Table 58 Europe Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
Table 59 Europe Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
Table 60 Europe Gabapentin Market Outlook, By Type (2021-2030) ($MN)
Table 61 Europe Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
Table 62 Europe Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
Table 63 Europe Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
Table 64 Europe Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 65 Europe Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
Table 66 Europe Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
Table 67 Europe Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
Table 68 Europe Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 69 Europe Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
Table 70 Europe Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
Table 71 Europe Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
Table 72 Europe Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
Table 73 Europe Gabapentin Market Outlook, By Application (2021-2030) ($MN)
Table 74 Europe Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
Table 75 Europe Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
Table 76 Europe Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
Table 77 Europe Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
Table 78 Europe Gabapentin Market Outlook, By End User (2021-2030) ($MN)
Table 79 Europe Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 80 Europe Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 81 Europe Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
Table 82 Asia Pacific Gabapentin Market Outlook, By Country (2021-2030) ($MN)
Table 83 Asia Pacific Gabapentin Market Outlook, By Product (2021-2030) ($MN)
Table 84 Asia Pacific Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
Table 85 Asia Pacific Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
Table 86 Asia Pacific Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
Table 87 Asia Pacific Gabapentin Market Outlook, By Type (2021-2030) ($MN)
Table 88 Asia Pacific Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
Table 89 Asia Pacific Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
Table 90 Asia Pacific Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
Table 91 Asia Pacific Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 92 Asia Pacific Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
Table 93 Asia Pacific Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
Table 94 Asia Pacific Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
Table 95 Asia Pacific Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 96 Asia Pacific Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
Table 97 Asia Pacific Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
Table 98 Asia Pacific Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
Table 99 Asia Pacific Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
Table 100 Asia Pacific Gabapentin Market Outlook, By Application (2021-2030) ($MN)
Table 101 Asia Pacific Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
Table 102 Asia Pacific Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
Table 103 Asia Pacific Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
Table 104 Asia Pacific Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
Table 105 Asia Pacific Gabapentin Market Outlook, By End User (2021-2030) ($MN)
Table 106 Asia Pacific Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 107 Asia Pacific Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 108 Asia Pacific Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
Table 109 South America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
Table 110 South America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
Table 111 South America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
Table 112 South America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
Table 113 South America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
Table 114 South America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
Table 115 South America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
Table 116 South America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
Table 117 South America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
Table 118 South America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 119 South America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
Table 120 South America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
Table 121 South America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
Table 122 South America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 123 South America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
Table 124 South America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
Table 125 South America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
Table 126 South America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
Table 127 South America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
Table 128 South America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
Table 129 South America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
Table 130 South America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
Table 131 South America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
Table 132 South America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
Table 133 South America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 134 South America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 135 South America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
Table 136 Middle East & Africa Gabapentin Market Outlook, By Country (2021-2030) ($MN)
Table 137 Middle East & Africa Gabapentin Market Outlook, By Product (2021-2030) ($MN)
Table 138 Middle East & Africa Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
Table 139 Middle East & Africa Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
Table 140 Middle East & Africa Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
Table 141 Middle East & Africa Gabapentin Market Outlook, By Type (2021-2030) ($MN)
Table 142 Middle East & Africa Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
Table 143 Middle East & Africa Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
Table 144 Middle East & Africa Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
Table 145 Middle East & Africa Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 146 Middle East & Africa Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
Table 147 Middle East & Africa Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
Table 148 Middle East & Africa Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
Table 149 Middle East & Africa Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 150 Middle East & Africa Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
Table 151 Middle East & Africa Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
Table 152 Middle East & Africa Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
Table 153 Middle East & Africa Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
Table 154 Middle East & Africa Gabapentin Market Outlook, By Application (2021-2030) ($MN)
Table 155 Middle East & Africa Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
Table 156 Middle East & Africa Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
Table 157 Middle East & Africa Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
Table 158 Middle East & Africa Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
Table 159 Middle East & Africa Gabapentin Market Outlook, By End User (2021-2030) ($MN)
Table 160 Middle East & Africa Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 161 Middle East & Africa Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 162 Middle East & Africa Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24790

According to Stratistics MRC, the Global Gabapentin Market is accounted for $2,171.52 million in 2023 and is expected to reach $3,567.61 million by 2030 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.

According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.

Market Dynamics:

Driver:

Increase in awareness

Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.

Restraint:

Misuse and abuse

Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.

Opportunity:

Telehealth expansion

The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market

Threat:

Side effects and tolerance

The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.

The capsule segment is expected to be the largest during the forecast period

The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment's growth.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment's expansion.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region's expansion.

Key players in the market

Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.

Key Developments:

In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.

In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.

Products Covered:

Tablet
Capsule
Other Products

Types Covered:

Generic
Branded
Other Types

Route of Administrations Covered:

Parenteral
Oral
Intravenous
Other Route of Administrations

Mode of Purchase Covered:

Prescription
Over the Counter(OTC)
Retail

Applications Covered:

Neuropathic Pain
Epilepsy
Restless Legs Syndrome
Other Applications

End Users Covered:

Online Pharmacies
Hospital Pharmacy
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Gabapentin Market, By Product

5.1 Introduction
5.2 Tablet
5.3 Capsule
5.4 Other Products

6 Global Gabapentin Market, By Type

6.1 Introduction
6.2 Generic
6.3 Branded
6.4 Other Types

7 Global Gabapentin Market, By Route of Administration

7.1 Introduction
7.2 Parenteral
7.3 Oral
7.4 Intravenous
7.5 Other Route of Administrations

8 Global Gabapentin Market, By Mode of Purchase

8.1 Introduction
8.2 Prescription
8.3 Over the Counter (OTC)
8.4 Retail

9 Global Gabapentin Market, By Application

9.1 Introduction
9.2 Neuropathic Pain
9.3 Epilepsy
9.4 Restless Legs Syndrome
9.5 Other Applications

10 Global Gabapentin Market, By End User

10.1 Introduction
10.2 Online Pharmacies
10.3 Hospital Pharmacy
10.4 Other End Users

11 Global Gabapentin Market, By Geography

11.1 Introduction
11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa

12 Key Developments

12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 Company Profiling

13.1 Amneal Pharmaceuticals LLC.
13.2 Intas Pharmaceuticals Ltd.
13.3 Sun Pharmaceutical Industries Ltd
13.4 Marksans Pharma
13.5 Novartis AG
13.6 Alkem Labs
13.7 Jiangsu Nhwa Pharmaceutical Co., Ltd
13.8 Aurobindo Pharma
13.9 Apotex Inc
13.10 Viatris Inc
13.11 Arbor Pharmaceuticals, LLC
13.12 Pfizer Inc
13.13 Teva Pharmaceuticals Ltd
13.14 Glenmark Pharmaceuticals Limited
13.15 Ascend Laboratories, LLC
13.16 Cipla USA, Inc.

ガバペンチン市場の2030年までの予測：製品タイプ、投与経路、購入形態、用途、エンドユーザー、地域別の世界分析

Gabapentin Market Forecasts to 2030 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography

最もシェアの高い地域

CAGRが最も高い地域：

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のガバペンチン市場：製品別

第6章 世界のガバペンチン市場：タイプ別

第7章 世界のガバペンチン市場：投与経路別

第8章 世界のガバペンチン市場：購入形態別

第9章 世界のガバペンチン市場：用途別

第10章 世界のガバペンチン市場：エンドユーザー別

第11章 世界のガバペンチン市場：地域別

第12章 主な発展

第13章 企業プロファイル